Inventiva
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
50 Rue De Dijon, Daix, Bourgogne-Franche...Phone Number
+33 380447500Website
www.inventivapharma.comRevenue
<$5 MillionStock Symbol
IVAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Inventiva
Inventiva is a clinical-stage biopharmaceutical company headquartered in France, specializing in the development of oral small molecule therapies. The company focuses on addressing significant unmet medical needs in areas such as fibrosis, lysosomal storage disorders, and oncology, aiming to advance innovative treatments that improve patient outcomes.Explore more
Inventiva Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inventiva your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Inventiva is spiking on competitors!
Click to see if Inventiva had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Inventiva has new funding data
Inventiva, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Inventiva recently announced quarterly report
Product Launch: Get notified when Inventiva launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Inventiva
Check if Inventiva has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Inventiva
Find 2 more new buyers
Company Profile Activity
Activity Insights
Inventiva is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Inventiva is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Inventiva.
Inventiva financials insights
Gather financial insights about Inventiva, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$16.4M
Stock Offering
$107.7M
2023
Share Placement
$36.7M
2024
Private Equity
$99.6M
2025
Debt
$131M
2026
Debt
$151.2M
Inventiva Tech Stack
A closer look at the technologies used by Inventiva
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Inventiva News & Media
Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development
Claret Capital Partners is providing growth funding of €43m as part of Inventiva’s €130m debt financing, to support its lead asset through Phase 3.Inventiva repays EIB loans, raises €75m in new debt | IVA SEC Filing - Form 6-K
Inventiva repaid its EIB loans and issued Tranche A convertible and Tranche B amortized bonds, raising €71.3m net, alongside warrants and a recent $4.40 ADS equity offering.Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and ...
Repaid in full the existing EIB Loans1 in an amount of approximately €62 million and completed repurchase of all 2,266,023 existing EIB Tranche A Warrants and 700,000 of existing EIB Tranche B Warrants2 (corresponding to approximately 22.7 million Underlying Shares) for a repurchase price of €50 million Issued the Tranche A Convertible Bonds (€35 million) and the Tranche B Amortized Bonds (€40 million), for an initial aggregate drawdown of €75 million under the Debt FinancingInventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
Daix (France), New York City (New York, United States), June 12, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the completion, on June 12, 2026, of the following key steps of the transactions previously announced on June 2, 2026 (the “Combined Transaction”): (i) the repayment in fu
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Inventiva
Sign Up For FreeTo access detailed company insights
Inventiva is a clinical-stage biopharmaceutical company headquartered in France, specializing in the development of oral small molecule therapies. The company focuses on addressing significant unmet medical needs in areas such as fibrosis, lysosomal storage disorders, and oncology, aiming to advance innovative treatments that improve patient outcom... Read More
